Artículo
Atlas of axial spondyloarthritis in Spain 2017: study design and population
Título alternativo | Atlas de Espondiloartritis Axial en España 2017: diseño del estudio y descripción de la muestra |
Autor/es | Garrido Cumbrera, Marco
![]() ![]() ![]() ![]() ![]() ![]() ![]() Navarro Compán, Victoria Zarco Montejo, Pedro Collantes Estévez, Eduardo Gálvez Ruiz, David ![]() ![]() ![]() ![]() ![]() ![]() ![]() Braçe, Olta ![]() ![]() ![]() ![]() ![]() Chacón García, Jorge Blanch, C. Costa Ferrer, Angels Hidalgo Vega, Álvaro Plazuelo Ramos, Pedro Gratacós, Jordi |
Departamento | Universidad de Sevilla. Departamento de Geografía Física y Análisis Geográfico Regional Universidad de Sevilla. Departamento de Geografía Humana Universidad de Sevilla. Departamento de Estadística e Investigación Operativa |
Fecha de publicación | 2019 |
Fecha de depósito | 2024-04-03 |
Publicado en |
|
Resumen | Objective
Atlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach.
Methods
The Atlas 2017 based its results on an ... Objective Atlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach. Methods The Atlas 2017 based its results on an extensive cross-sectional patient survey conducted in Spain (2016), validated by a multidisciplinary group of experts on spondyloarthritis. Results Data from 680 patients with axSpA were obtained, most of them suffered from AS, were HLA-B27 positive, older than 45 years, and live as part of a couple. A large percentage had university studies, were disabled and members of a patient association. Patients reported a diagnostic delay of 8.5 years, high disease activity (BASDAI 5.5 ± 2.2), moderate-important stiffness (61.0%), medium-high functional limitation (74.9%), and psychological distress (GHQ 5.7 ± 4.5). A total of 54.7% reported taking NSAIDs, 28.4% DMARDs, 36.3% biological therapy and 32.2% were not receiving pharmacological treatment. Conclusions The Atlas survey data reveals still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated. |
Cita | Garrido-Cumbrera, M., Navarro-Compán, V., Zarco, P., Collantes-Estévez, E., Gálvez-Ruiz, D., Braçe, O., ... & Masmitja, J. G. (2019). Atlas of axial spondyloarthritis in Spain 2017: study design and population. Reumatología Clínica (English Edition), 15(3), 127-132. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
2019_Atlas of axial spondyloar ... | 786.2Kb | ![]() | Ver/ | Preprint |